#ESMOGyn24 - Twitter Hashtag

about 2 years ago

Dostarlimab plus chemotherapy, followed by dostarlimab alone, improved OS vs placebo plus chemo in patients with primary advanced/recurrent endometrial cancer, with benefits observed across molecular subgroups. @SarahCannonDocs @myESMO #ESMOGYN24 #gynsm https://t.co/utRT1raREr

0

2

0

866

OncLive.com

@OncLive

about 2 years ago

Dostarlimab plus chemotherapy significantly improved OS in advanced or recurrent endometrial cancer, with a median OS of 44.6 months vs 28.2 months for placebo. @SarahCannonDocs @myESMO #ESMOGYN24 #gynsm #oncology https://t.co/utRT1raREr

OncLive's tweet photo. Dostarlimab plus chemotherapy significantly improved OS in advanced or recurrent endometrial cancer, with a median OS of 44.6 months vs 28.2 months for placebo. @SarahCannonDocs @myESMO #ESMOGYN24 #gynsm #oncology https://t.co/utRT1raREr https://t.co/5BaXn99HSY

0

3

0

1K

OncLive.com

@OncLive

about 2 years ago

Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer @SarahCannonDocs @myESMO #ESMOGYN24 #gynsm #oncology https://t.co/utRT1raREr

0

3

0

1

627

GEICO-Spanish Gynaecological Cancer Research Group

@GEICOgroup

over 2 years ago

También estuvo en #ESMOGYN24 @PerezFidal que expuso en la sesión educacional del pasado sábado la presentación "Expanding our therapeutic armamentarium: ADCs in the ovarian cancer field" en la que habló sobre targeting NAPI2B. #formaciónmédica #investigación #teamGEICO